RT期刊文章SR电子T1的自然病程和预后主要脊髓胶质母细胞瘤摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP e1497 OP e1509 10.1212 / 首页WNL。100签证官0000000000206834是14 A1 Aymeric麦洛A1 Louis-Marie梗A1 Bertrand Mathon A1克利斯朵夫Joubert A1 Thiebaud Picart A1文森特Jecko A1 Luc Bauchet A1 Florian伯纳德A1 Xavier卡斯特尔A1路易Chenin A1 Ann-Rose库克A1伊金刚砂A1多米尼克Figarella-Branger A1 Guillaume Gauchotte A1托马斯Graillon A1安妮Jouvet A1米歇尔Kalamarides A1史蒂文Knafo A1 Arnaud Lazard A1文森特Lubrano A1 (Karima Mokhtari称A1 Valerie Rigau A1文森特Roualdes A1奥黛丽卢梭A1 Romuald Seizeur A1 Emmanuelle Uro-Coste A1吉米Voirin A1菲利普Metellus A1 Johan Pallud A1 Ilyess Zemmoura A1和髓胶质母细胞瘤研究小组2023年UL //www.ez-admanager.com/content/100/14/e1497.abstract AB背景和目标主要脊髓胶质母细胞瘤(PsGBM)是极为罕见。首页戏剧性的神经恶化和由PsGBM使它特别禁用恶性肿瘤。因为它是一种罕见的和异构疾病,预后因素的评估仍然是有限的。方法确定PsGBMs从法国脑瘤数据库和俱乐部de Neuro-Oncologie法国Neurochirurgie回顾性的法国。入选标准是18岁或以上诊断,脊椎位置,新胶质母细胞瘤的病理诊断根据2016年世界卫生组织分类,和手术管理在2004年和2016年之间。诊断证实了一个集中neuropathologic审查。主要结果是总生存期(OS)。治疗性干预措施和神经的结果也被收集。结果33组织病理学证实PsGBM患者(平均年龄50.9岁)包括(中心27日)。 The median OS was 13.1 months (range 2.5–23.7), and the median progression-free survival was 5.9 months (range 1.6–10.2). In multivariable analyses using Cox model, Eastern Cooperative Oncology Group (ECOG) performance status at 0–1 was the only independent predictor of longer OS (hazard ratio [HR] 0.13, 95% CI 0.02–0.801; p = 0.02), whereas a Karnofsky performance status (KPS) score <60 (HR 2.89, 95% CI 1.05–7.92; p = 0.03) and a cervical anatomical location (HR 4.14, 95% CI 1.32–12.98; p = 0.01) were independent predictors of shorter OS. The ambulatory status (Frankel D–E) (HR 0.38, 95% CI 0.07–1.985; p = 0.250) was not an independent prognostic factor, while the concomitant standard radiochemotherapy with temozolomide (Stupp protocol) (HR 0.35, 95% CI 0.118–1.05; p = 0.06) was at the limit of significance.Discussion Preoperative ECOG performance status, KPS score, and the location are independent predictors of OS of PsGBMs in adults. Further analyses are required to capture the survival benefit of concomitant standard radiochemotherapy with temozolomide.CT=chemotherapy; ECOG=Eastern Cooperative Oncology Group; FBTDB=French Brain Tumor Database; FLAIR=fluid-attenuated inversion recovery; FU=follow-up; GBM=glioblastoma; HR=hazard ratio; IDH=isocitrate dehydrogenase; KPS=Karnofsky performance status; MGMT=O(6)-methylguanine-DNA methyltransferase; OS=overall survival; PFS=progression-free survival; PsGBM=primary spinal glioblastoma; RENOCLIP=Réseau de Neuro-Oncologie CLInico Pathologique; RENOP=Réseau de Neuro-oncologie pathologique; RT=radiotherapy; STR=subtotal resection surgery; TERT=telomerase reverse transcriptase; WHO=World Health Organization

map